RMTI Rockwell Medical, Inc. - Common Stock
NASDAQ · Health Care · Wyświetl na SEC EDGAR ↗ zamknij Paź 2, 2026 10-K/10-Q Sie 13, 2026
$8,65
· % zakresu 52 tyg.
· powyżej minimum
· do maksimum
$0,6052tyg. minimum
$8,9052tyg. maksimum
Kapitalizacja Rynkowa (MRQ)
$34M
P/E (TTM)
-10.8
EPS (TTM)
$-0.80
Przychody (TTM)
$69M
Twoje odznaki
Zakres 52 tyg.
$1–$9
Ocena Analityków
BUY
Cena Docelowa
$20
P/E
-10.8
ROE
-15.5%
Marża Zysku Netto
-7.3%
Twój pasek odznak jest pusty — przypnij metrykę w dowolnym miejscu na tej stronie.
RMTI Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$8.65
Kapitalizacja Rynkowa (MRQ)
$34M
P/E (TTM)
-10.8
EPS (TTM)
$-0.80
Przychody (TTM)
$69M
ROE (TTM)
-15.5%
D/E Dług/Kapitał (MRQ)
0.3
Zakres 52 tyg.
$1–$9
RMTI Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
zakres
kreski
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
Podziały akcji
| Data ex-dywidendy | Podział | Typ |
|---|---|---|
| 1 lipca 2026 | 1-for-10 | Odwrotny |
| 13 maja 2022 | 1-for-11 | Odwrotny |
O Rockwell Medical, Inc. - Common Stock Przegląd firmy z Wikipedii
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
The company's primary customers are dialysis providers.
Products
Triferic
Triferic was approved by the Food and Drug Administration (FDA) in January 2015. Triferic is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. Triferic replaces the iron lost during hemodialysis treatments. Triferic delivers iron directly to transferrin which transports it to the bone marrow to make hemoglobin. Rockwell is actively marketing and commercializing Triferic in the U.S. hemodialysis market. In February 2014, the Company completed its long-term safety study for Triferic.
Rockwell Medical began commercializing Triferic (dialysate) and Triferic AVNU (intravenous) in the United States in the second half of 2019 and in early 2021, respectively. Triferic was launched into a very competitive marketplace with well-entrenched products and a lack of consensus regarding unmet medical needs for dialysis patients with anemia. Due to its limited market adoption, unfavorable reimbursement, and absence of interest from other companies to license or acquire Triferic despite Rockwell's significant effort to partner the program, Rockwell Medical discontinued its New Drug Applications (“NDAs”) for Triferic and Triferic AVNU in the United States in the fourth quarter of 2022.
Calcitriol
Calcitriol (active vitamin D) generic is FDA approved for treating secondary hyperparathyroidism or hypocalcemia in hemodialysis patients.
Hemodialysis Concentrates
Rockwell is a manufacturer of hemodialysis concentrates/dialysates for dialysis providers and distributors in the U.S. and globally. Hemodialysis concentrates remove toxins and replace critical nutrients in the dialysis patient's bloodstream during hemodialysis. Rockwell has three U.S. manufacturing and distribution facilities.
Iron (III) pyrophosphate
One of the main treatments that the company develops is iron (III) pyrophosphate, for iron supplementation, a key element in the formation of new red blood cells. It was licensed in 2011 for the delivery of iron supplementation for patients who suffer from anemic dialysis since the process accounts for treatment in around 90% of anemia patients.
International Partnerships
While Rockwell has discontinued commercialization of Triferic in the United States, the company has established international partnerships with companies seeking to develop and commercialize Triferic outside the United States and is working closely with these international partners to develop and commercialize Triferic in their respective regions.
South Korea for example; Triferic and Triferic AVNU have been approved in South Korea, and our partner, Jeil Pharmaceutical, launched Triferic in South Korea during the third quarter of 2022.
Also, in April 2023, Drogsan submitted a Marketing Authorization application and GMP application for Triferic AVNU to the Turkish Medicines and Medical Devices Agency ("TMMDA"), for which Drogsan received priority status and high priority status, respectively. Taking into consideration that Drogsan was granted an accelerated review for Triferic AVNU with the Turkish regulatory authority, Rockwell anticipates approval for Triferic AVNU in Turkey in 2024. Drogsan is responsible for all regulatory approval and commercialization activities.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
sektorHealth Care
branżaHealth Care
pracownicy157
krajUS
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody$69M2016-12-31 → 2025-12-31
EPS$-0.152016-12-31 → 2025-12-31
Wolny przepływ pieniężny$-1M2024-12-31 → 2025-12-31
Marża netto-7.3%2016-12-31 → 2025-12-31
Wycena i wskaźniki
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | RMTI | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | -10.8średnia z 5 lat ≈-16.1 | ≈-16.1 | · | · | |
| P/S (TTM) | 0.5średnia z 5 lat ≈1.8 | ≈1.8 | 1.9 | Niedowartościowany | |
| P/B (MRQ) | 1.0średnia z 5 lat ≈34.7 | ≈34.7 | 0.8 | Niedowartościowany | |
| EV / EBITDA | -12.9średnia z 5 lat ≈-3.1 | ≈-3.1 | · | · | |
| Cena / FCF (TTM) | 22.3 | · | · | · | |
| Cena / Przepływy pieniężne (TTM) | 11.9średnia z 5 lat ≈-10.5 | ≈-10.5 | · | · | |
| EV / Revenue (EV / Przychody) | 0.5średnia z 5 lat ≈1.8 | ≈1.8 | · | · | |
| EV / FCF | -26.9 | · | · | · | |
| Cena / Wartość księgowa materialna (MRQ) | 1.3średnia z 5 lat ≈54.8 | ≈54.8 | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | RMTI | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Marża brutto (TTM) | 17.7%średnia z 5 lat ≈9.2% | ≈9.2% | 39.2% | Słaby | |
| Marża Operacyjna (TTM) | -6.5%średnia z 5 lat ≈-17.2% | ≈-17.2% | -40.8% | Najwyższa półka | |
| Marża EBITDA (TTM) | -3.5%średnia z 5 lat ≈-15.5% | ≈-15.5% | -23.4% | Najwyższa półka | |
| Pretax Margin (Marża przed opodatkowaniem) | -7.7% | · | -35.6% | Najwyższa półka | |
| Marża Zysku Netto (TTM) | -7.3%średnia z 5 lat ≈-19.3% | ≈-19.3% | -47.1% | Najwyższa półka | |
| ROA (TTM) | -9.3%średnia z 5 lat ≈-23.6% | ≈-23.6% | -29.3% | Najwyższa półka | |
| ROE (TTM) | -15.5%średnia z 5 lat ≈-132.0% | ≈-132.0% | -72.5% | Najwyższa półka | |
| ROIC | -10.2% | · | -17.5% | Najwyższa półka |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | RMTI | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | 0.3średnia z 5 lat ≈1.9 | ≈1.9 | · | · | |
| Wskaźnik bieżący (MRQ) | 3.3średnia z 5 lat ≈2.4 | ≈2.4 | 4.1 | Niska płynność | |
| Quick Ratio (Wskaźnik Szybkości) | 2.0średnia z 5 lat ≈1.3 | ≈1.3 | 2.8 | Niska płynność | |
| Dług długoterminowy / Kapitał własny (MRQ) | 0.2średnia z 5 lat ≈1.3 | ≈1.3 | · | · |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | RMTI | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | -31.8%średnia z 5 lat ≈4.3% | ≈4.3% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | -1.7%średnia z 5 lat ≈8.9% | ≈8.9% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 2.2% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | RMTI | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 1.2średnia z 5 lat ≈1.4 | ≈1.4 | 0.4 | Najwyższa półka | |
| Inventory Turnover (Rotacja zapasów) | 12.5średnia z 5 lat ≈14.0 | ≈14.0 | 2.0 | Najwyższa półka | |
| Receivables Turnover (Rotacja należności) | 8.4średnia z 5 lat ≈10.6 | ≈10.6 | 7.9 | Najwyższa półka | |
| Revenue / Employee (Przychody / pracownika) | ≈$441.1K | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
-61.6%
Następny raport
Lis 10, 2026
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Sie 13, 2026 | $-0.34 | $-0.24 | -41.8% |
| 31 marca 2026 | Maj 7, 2026 | $-0.40 | $-0.26 | -56.9% |
| 31 grudnia 2025 | $-0.10 | $0.20 | -149.0% | |
| 30 września 2025 | $-0.50 | $-0.46 | -8.9% | |
| 30 czerwca 2025 | $-0.50 | $-0.51 | 2.0% | |
| 31 marca 2025 | $-0.04 | $-0.05 | 21.6% | |
| 31 grudnia 2024 | $-0.02 | $0.02 | -198.0% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M | $55M | $54M | |
| Cost of Revenue | $58M | $84M | $75M | $69M | $64M | $59M | $58M | $65M | $54M | $47M | $46M | $46M | |
| Gross Profit | $12M | $17M | $9M | $4M | $-2M | $3M | $3M | $-2M | $4M | $7M | $9M | $9M | |
| R&D Expense | $0 | $19.0K | $1M | · | · | · | · | $6M | $6M | $6M | $5M | $8M | |
| SG&A Expense | $14M | $14M | $12M | $16M | $15M | $16M | $21M | $22M | $23M | $21M | $19M | $18M | |
| Operating Income | $-5M | $608.0K | $-7M | $-17M | $-30M | $-28M | $-35M | $-32M | $-26M | $-20M | $-15M | $-18M | |
| Interest Expense | · | · | $2M | $2M | $2M | $2M | $25.0K | · | · | · | · | · | |
| Interest Income | · | · | $211.0K | $33.0K | $22.0K | $238.0K | $392.0K | · | · | · | · | · | |
| Other Non-op | $-623.0K | $-1M | $-2M | $-2M | $-2M | $-2M | $397.0K | $313.3K | $1.6K | · | · | · | |
| Pretax Income | $-5M | $-480.0K | $-8M | · | · | · | · | · | $-26M | $-19M | $-14M | $-21M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $404.5K | $0 | $0 | |
| Net Income | $-5M | $-480.0K | $-8M | $-19M | $-33M | $-31M | $-34M | $-32M | $-26M | $-20M | $-14M | $-21M | |
| EPS (Basic) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | · | · | $-0.51 | $-0.39 | $-0.29 | $-0.52 | |
| EPS (Diluted) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | · | · | $-0.51 | $-0.39 | $-0.29 | $-0.52 | |
| Shares (Basic) | 35,974,231 | 31,058,539 | 23,322,915 | 14,304,512 | 8,526,186 | 75,621,674 | · | · | 51,067,412 | 50,676,180 | 50,068,129 | 41,404,999 | |
| Shares (Diluted) | 35,974,231 | 31,058,539 | 23,322,915 | 14,304,512 | 8,526,186 | 75,621,674 | · | · | 51,067,412 | 50,676,180 | 50,068,129 | 41,404,999 | |
| EBITDA | $-2M | $3M | $-5M | $-16M | $-30M | $-28M | $-34M | $-32M | $-25M | $-19M | $-14M | $-17M |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $16M | $9M | $10M | $13M | $49M | $12M | $23M | $8M | $17M | $31M | $66M | |
| Short-term Investments | · | · | · | · | · | · | · | $11M | $25M | $41M | $39M | $20M | |
| Receivables | $8M | $8M | $11M | $6M | $6M | $4M | $4M | $7M | $6M | $6M | $5M | $4M | |
| Inventory | $3M | $6M | $6M | $6M | $4M | $4M | $4M | $4M | $8M | $12M | $8M | $4M | |
| Prepaid Expense | $2M | $1M | $1M | $2M | $3M | $3M | $3M | $2M | $2M | · | · | · | |
| Other Current Assets | · | · | · | · | · | · | · | · | $2M | $2M | $1M | $587.2K | |
| Current Assets | $38M | $37M | $29M | $35M | $35M | $69M | $37M | $47M | $49M | $79M | $85M | $95M | |
| PP&E (Net) | $5M | $6M | $6M | $2M | $2M | $3M | $2M | $3M | $3M | $1M | $2M | $1M | |
| PP&E (Gross) | $15M | $16M | $15M | $10M | $10M | $9M | $8M | $9M | $12M | $11M | $11M | $10M | |
| Accum. Depreciation | $11M | $10M | $9M | $8M | $7M | $7M | $6M | $6M | $9M | $10M | $9M | $9M | |
| Goodwill | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $920.7K | $920.7K | $920.7K | $920.7K | $920.7K | |
| Intangibles | $10M | $10M | $11M | $0 | · | · | · | · | $4.0K | $4.4K | $165.7K | $332.7K | |
| Other Non-current Assets | $556.0K | $528.0K | $527.0K | $523.0K | $619.0K | $629.0K | $435.0K | $536.5K | $494.8K | $501.2K | $462.8K | $542.2K | |
| Total Assets | $57M | $59M | $52M | $47M | $49M | $78M | $44M | $53M | $59M | $83M | $88M | $98M | |
| Accounts Payable | $2M | $3M | $5M | $4M | $4M | $4M | $3M | $4M | $4M | $6M | $4M | $5M | |
| Accrued Liabilities | $4M | $6M | $7M | $8M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | |
| Current Liabilities | $10M | $14M | $17M | $18M | $21M | $13M | $12M | $13M | $9M | $10M | $8M | $10M | |
| Capital Leases | $1M | $2M | $1M | $3M | · | $2M | $2M | · | · | · | · | · | |
| Other Non-current Liabilities | · | $0 | $14.0K | $14.0K | $14.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $20M | $27M | $31M | $33M | $46M | $44M | $24M | $25M | $26M | · | · | · | |
| Long-term Debt | $9M | · | $8M | $9M | $21M | $21M | · | · | · | · | · | · | |
| Total Debt | $9M | $8M | $8M | $9M | $21M | $21M | · | · | · | · | · | · | |
| Common Stock | · | · | · | · | · | · | · | · | · | $268M | $258M | $249M | |
| Paid-in Capital | $440M | $430M | $418M | $403M | $373M | $372M | $327M | $300M | · | · | · | · | |
| Retained Earnings | $-403M | $-398M | $-397M | $-389M | $-370M | $-337M | $-307M | $-272M | $-240M | $-214M | $-195M | $-180M | |
| AOCI | $131.0K | $54.0K | $-1.0K | $163.0K | $52.0K | $57.0K | $52.0K | $63.1K | $-35.4K | $-902.5K | $-915.5K | $-197.7K | |
| Stockholders' Equity | $37M | $33M | $21M | $14M | $3M | $34M | $20M | $27M | $33M | $53M | $62M | $69M | |
| Liabilities + Equity | $57M | $59M | $52M | $47M | $49M | $78M | $44M | $53M | $59M | $83M | $88M | $98M | |
| Shares Outstanding | 3,940,530 | 3,405,692 | 29,130,607 | 12,163,673 | 8,544,225 | 8,506,651 | 65,378,890 | 57,034,154 | 51,768,424 | 51,527,711 | 51,501,877 | 50,284,007 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $1M | $576.0K | $668.0K | $834.0K | $788.0K | $650.1K | $514.4K | $762.4K | $822.3K | $996.3K | |
| Stock-based Comp | $2M | $1M | $932.0K | $315.0K | $943.0K | $475.0K | $5M | $4M | $7M | $10M | $9M | $10M | |
| Amort. of Intangibles | · | · | $300.0K | · | · | · | · | · | · | · | · | · | |
| Restructuring | $1M | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-966.0K | $-317.0K | $-11M | $-2M | $-7M | $-3M | $-887.5K | $3M | $-6M | $-8M | $-20M | $27M | |
| Operating Cash Flow | $-659.0K | $4M | $-9M | $-17M | $-34M | $-30M | $-27M | $-20M | $-21M | $-12M | $-13M | $4M | |
| CapEx | $542.0K | $1M | $284.0K | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $-9M | $-5M | $-3M | $-2M | $311.0K | $3M | $-5M | $13M | $15M | $-2M | $-21M | $-9M | |
| Debt Issued | · | · | · | · | $0 | $22M | $0 | · | · | · | · | · | |
| Net Debt Issued | · | · | · | · | $0 | $22M | · | · | · | · | · | · | |
| Stock Issued | $8M | $10M | $15M | $15M | · | · | $5M | $22M | $123.6K | · | · | · | |
| Net Stock Activity | $8M | $10M | $15M | · | · | · | · | $22M | · | · | · | · | |
| Financing Cash Flow | $4M | $7M | $11M | $16M | $-2M | $63M | $21M | $22M | $-2M | $80.2K | $-132.7K | $58M | |
| Net Change in Cash | $-5M | $7M | $-1M | $-3M | $-35M | $37M | $-11M | $14M | $-9M | $-14M | $-35M | $54M | |
| Taxes Paid | $0 | · | · | · | · | · | · | · | · | $404.5K | · | · | |
| Free Cash Flow | $-1M | $3M | · | · | · | · | · | · | · | · | · | · |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% | 4.4% | 4.6% | -2.5% | 6.5% | 12.7% | 16.2% | 15.8% | |
| Operating Margin | -6.8% | 0.60% | -8.0% | -23.1% | -49.0% | -45.7% | -56.3% | -51.2% | -45.2% | -37.9% | -27.3% | -32.4% | |
| Net Margin | -7.7% | -0.47% | -10.1% | -25.7% | -52.8% | -49.7% | -55.7% | -50.7% | -45.2% | -37.2% | -26.1% | -39.4% | |
| Pretax Margin | -7.7% | -0.47% | · | · | · | · | · | · | -45.2% | -36.4% | -26.1% | -39.4% | |
| EBITDA Margin | -3.6% | 2.8% | -6.2% | -22.3% | -47.9% | -44.4% | -55.0% | -50.1% | -44.3% | -36.5% | -25.8% | -30.6% | |
| ROA | -9.1% | -0.86% | -17.1% | -39.2% | -51.7% | -50.6% | -70.5% | -57.7% | -36.5% | -23.2% | -15.5% | -31.8% | |
| ROE | -15.8% | -1.6% | -39.4% | -123.5% | -479.5% | -81.0% | -155.1% | -160.8% | -60.4% | -34.4% | -22.0% | -61.6% | |
| ROIC | -10.2% | 1.5% | · | · | · | · | · | · | -78.8% | -39.0% | -24.2% | -25.6% |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.0 | 2.6 | 1.7 | 2.0 | 1.7 | 5.4 | 3.0 | 3.5 | 5.3 | 7.7 | 10.5 | 9.7 | |
| Quick Ratio | 2.0 | 1.7 | 1.2 | 0.9 | 0.9 | 4.1 | 1.3 | 3.1 | 4.3 | 6.3 | 9.4 | 9.2 | |
| Debt / Equity | 0.2 | 0.3 | 0.4 | 0.7 | 8.1 | 0.6 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.2 | 0.3 | 0.4 | 0.5 | 5.2 | 0.6 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -2.9 | -8.7 | -12.9 | -15.1 | · | · | · | · | · | · |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.2 | 1.8 | 1.7 | 1.5 | 1.0 | 1.0 | 1.3 | 1.1 | 0.8 | 0.6 | 0.6 | 0.8 | |
| Inventory Turnover | 12.5 | 14.4 | 12.8 | 13.9 | 16.1 | 15.7 | 15.2 | 11.1 | 5.4 | 4.7 | 7.9 | 13.6 | |
| Receivables Turnover | 8.4 | 10.6 | 9.7 | 12.0 | 12.3 | 14.9 | 11.0 | 9.5 | 9.0 | 9.3 | 11.6 | 12.0 |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.94 | $0.96 | $0.73 | $1.16 | $0.03 | $0.37 | $0.31 | $0.48 | $0.64 | $1.03 | $1.21 | $1.37 | |
| Revenue / Share | $1.93 | $3.27 | $3.58 | $7.38 | $0.66 | · | · | · | $1.12 | $1.05 | $1.11 | $1.31 | |
| Cash Flow / Share | $-0.02 | $0.14 | $-0.40 | $-1.76 | $-0.36 | · | · | · | $-0.41 | $-0.25 | $-0.32 | $0.10 | |
| Cash / Share | $0.27 | $0.46 | $0.31 | $0.83 | $0.14 | $0.52 | $0.18 | $0.40 | $0.16 | $0.33 | $0.61 | $1.31 | |
| EPS (TTM) | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 | $-0.41 | $-0.46 | $-0.46 | $-0.51 | $-0.39 | $-0.29 | $-0.52 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -31.8% | 21.4% | 14.8% | 17.6% | -0.43% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -1.7% | 17.9% | 10.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 2.2% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $69M | $101M | $84M | $73M | $62M | $62M | $61M | $63M | $57M | $53M | $55M | $54M | |
| Net Income TTM | $-5M | $-480.0K | $-8M | $-19M | $-33M | $-31M | $-34M | $-32M | $-26M | $-20M | $-14M | $-21M | |
| Market Cap | $33M | $69M | $55M | $12M | $424M | $1.04B | $1.75B | $1.42B | $3.31B | $3.71B | $5.80B | $5.69B | |
| Enterprise Value | $31M | $62M | $54M | $11M | $431M | $1.01B | · | · | · | · | · | · | |
| P/E | -5.5 | -68.0 | -5.1 | -0.8 | -1.2 | -27.1 | -58.3 | -54.0 | -125.5 | -184.7 | -388.4 | -217.5 | |
| P/S | 0.5 | 0.7 | 0.7 | 0.2 | 6.8 | 16.7 | 28.6 | 22.4 | 57.8 | 69.7 | 104.8 | 104.9 | |
| P/B | 0.9 | 2.1 | 2.6 | 0.9 | 167.2 | 30.4 | 86.4 | 52.0 | 100.7 | 70.1 | 93.1 | 82.8 | |
| P / Tangible Book | 1.2 | 3.2 | 5.7 | 0.9 | 262.6 | 31.3 | · | · | · | · | · | · | |
| P / Cash Flow | -49.6 | 16.5 | -5.8 | -0.7 | -12.6 | -35.1 | -64.3 | -69.4 | -157.0 | -298.1 | -357.2 | 1335.5 | |
| P / FCF | -27.2 | 21.8 | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -12.3 | 22.3 | -10.4 | -0.7 | -14.5 | -36.7 | · | · | · | · | · | · | |
| EV / FCF | -25.7 | 19.5 | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 0.4 | 0.6 | 0.7 | 0.2 | 7.0 | 16.3 | · | · | · | · | · | · | |
| Earnings Yield | -18.1% | -1.5% | -19.6% | -129.7% | -84.9% | -3.7% | -1.7% | -1.8% | -0.80% | -0.54% | -0.26% | -0.46% |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $18M | $17M | $18M | $16M | $16M | $19M | $25M | $28M | $26M | $23M | $22M | $24M | $18M | $20M | $19M | $19M | |
| Cost of Revenue | $15M | $14M | $14M | $14M | $14M | $16M | $21M | $22M | $21M | $20M | $19M | $22M | $17M | $17M | $17M | $18M | |
| Gross Profit | $3M | $3M | $4M | $2M | $3M | $3M | $4M | $6M | $5M | $3M | $3M | $2M | $1M | $3M | $2M | $777.0K | |
| R&D Expense | $40.0K | · | $0 | $0 | $0 | $0 | $1.0K | $0 | $0 | $18.0K | $168.0K | $494.0K | $167.0K | $278.0K | · | $469.0K | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $4M | $3M | $4M | $3M | $4M | $3M | $3M | $3M | $3M | $4M | $3M | |
| Operating Income | $-1M | $-1M | $-398.0K | $-2M | $-1M | $-1M | $-519.0K | $2M | $515.0K | $-1M | $-547.0K | $-2M | $-3M | $-1M | $-2M | $-4M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $431.0K | · | $411.0K | $395.0K | $387.0K | $435.0K | $476.0K | |
| Other Non-op | $-111.0K | $-125.0K | $-156.0K | $-169.0K | $-143.0K | $-155.0K | $-237.0K | $-272.0K | $-172.0K | $-407.0K | $-965.0K | $-135.0K | $-346.0K | $-323.0K | $-396.0K | $-482.0K | |
| Net Income | $-1M | $-2M | $-554.0K | $-2M | $-1M | $-2M | $-756.0K | $2M | $343.0K | $-2M | $-2M | $-2M | $-3M | $-2M | $-2M | $-4M | |
| EPS (Basic) | $-0.34 | $-0.04 | $-0.01 | $-0.05 | $-0.48 | $-0.04 | $-0.03 | $0.05 | $0.01 | $-0.06 | $-0.02 | $-0.07 | $-0.18 | $-0.10 | $0.19 | $-0.23 | |
| EPS (Diluted) | $-0.70 | $-0.04 | $-0.01 | $-0.05 | $-0.05 | $-0.04 | $-0.02 | $0.04 | $0.01 | $-0.06 | $-0.02 | $-0.07 | $-0.18 | $-0.10 | $0.19 | $-0.23 | |
| Shares (Basic) | 3,958,568 | 39,418,302 | · | 36,024,940 | 3,431,130 | 34,107,640 | · | 31,551,805 | 30,451,622 | 29,327,204 | · | 27,521,088 | 18,496,640 | 18,359,940 | · | 18,463,673 | |
| Shares (Diluted) | 3,958,568 | 39,418,302 | · | 36,024,940 | 3,431,130 | 34,107,640 | · | 32,420,168 | 32,033,776 | 29,327,204 | · | 27,521,088 | 18,496,640 | 18,359,940 | · | 18,463,673 | |
| EBITDA | $-1M | $-969.0K | · | $-2M | $-1M | $-821.0K | · | $2M | $515.0K | $-779.0K | · | $-2M | $-3M | $-1M | · | $-4M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11M | $10M | $11M | $14M | $12M | $11M | $16M | $12M | $12M | $7M | $9M | $8M | $9M | $11M | $10M | $13M | |
| Receivables | $8M | $9M | $8M | $8M | $8M | $10M | $8M | $9M | $11M | $11M | $11M | $9M | $5M | $6M | $6M | $7M | |
| Inventory | $3M | $3M | $3M | $4M | $4M | $5M | $6M | $6M | $6M | $6M | $6M | $5M | $6M | $6M | $6M | $5M | |
| Prepaid Expense | $441.0K | $1M | $2M | $2M | $943.0K | $988.0K | $1M | $1M | $1M | $910.0K | $1M | $2M | $1M | $1M | $2M | $2M | |
| Current Assets | $36M | $37M | $38M | $38M | $32M | $33M | $37M | $34M | $30M | $27M | $29M | $28M | $28M | $30M | $35M | $42M | |
| PP&E (Net) | $5M | $4M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $7M | $2M | $2M | $2M | $2M | |
| PP&E (Gross) | $14M | $14M | $15M | $16M | $16M | $16M | $16M | $16M | $16M | $15M | $15M | $15M | $10M | $10M | $10M | $10M | |
| Accum. Depreciation | $9M | $10M | $11M | $12M | $11M | $11M | $10M | $10M | $10M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | |
| Goodwill | $920.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | $921.0K | |
| Intangibles | $9M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $10M | $11M | $11M | $11M | · | · | $0 | · | |
| Other Non-current Assets | $556.0K | $556.0K | $556.0K | $561.0K | $561.0K | $521.0K | $528.0K | $548.0K | $548.0K | $527.0K | $527.0K | $527.0K | $527.0K | $522.0K | $523.0K | $522.0K | |
| Total Assets | $57M | $57M | $57M | $57M | $53M | $54M | $59M | $57M | $53M | $51M | $52M | $53M | $38M | $40M | $47M | $54M | |
| Accounts Payable | $3M | $3M | $2M | $2M | $2M | $2M | $3M | $3M | $3M | $5M | $5M | $4M | $6M | $5M | $4M | $3M | |
| Accrued Liabilities | $4M | $3M | $4M | $4M | $4M | $5M | $6M | $6M | $6M | $5M | $7M | $7M | $4M | $4M | $8M | $6M | |
| Current Liabilities | $11M | $10M | $10M | $10M | $11M | $11M | $14M | $14M | $15M | $15M | $17M | $21M | $17M | $15M | $18M | $19M | |
| Capital Leases | $3M | $3M | $1M | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $1M | $2M | $2M | $2M | $3M | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | $14.0K | |
| Total Liabilities | $21M | $22M | $20M | $20M | $22M | $22M | $27M | $28M | $30M | $30M | $31M | $31M | $29M | $28M | $33M | $38M | |
| Long-term Debt | $9M | $9M | · | · | · | · | · | · | · | · | · | $9M | $9M | $9M | $9M | $14M | |
| Total Debt | $9M | $9M | · | $9M | $9M | $9M | · | $8M | $8M | $8M | · | $9M | $9M | $9M | · | $14M | |
| Paid-in Capital | $441M | $440M | $440M | $439M | $431M | $431M | $430M | $426M | $422M | $420M | $418M | $417M | $403M | $403M | $403M | $402M | |
| Retained Earnings | $-406M | $-405M | $-403M | $-402M | $-401M | $-399M | $-398M | $-397M | $-399M | $-399M | $-397M | $-396M | $-394M | $-391M | $-389M | $-386M | |
| AOCI | $130.0K | $133.0K | $131.0K | $73.0K | $57.0K | $60.0K | $54.0K | $8.0K | $-5.0K | $24.0K | $-1.0K | $68.0K | $137.0K | $156.0K | $163.0K | $54.0K | |
| Stockholders' Equity | $35M | $36M | $37M | $37M | $30M | $32M | $33M | $29M | $23M | $21M | $21M | $22M | $10M | $13M | $14M | $16M | |
| Liabilities + Equity | $57M | $57M | $57M | $57M | $53M | $54M | $59M | $57M | $53M | $51M | $52M | $53M | $38M | $40M | $47M | $54M | |
| Shares Outstanding | 3,972,029 | 39,470,299 | 39,405,302 | 39,405,301 | 34,430,352 | 34,257,903 | 34,056,920 | 32,318,806 | 31,030,218 | 29,556,474 | 29,130,607 | 28,489,663 | 16,795,673 | 12,552,673 | 12,163,673 | 11,152,673 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $492.0K | $511.0K | $546.0K | $544.0K | $563.0K | $539.0K | $543.0K | $543.0K | $549.0K | $545.0K | $550.0K | $564.0K | $170.0K | $160.0K | $154.0K | $143.0K | |
| Stock-based Comp | $403.0K | $479.0K | $457.0K | $532.0K | $382.0K | $445.0K | $382.0K | $321.0K | $338.0K | $251.0K | $218.0K | $212.0K | $309.0K | $193.0K | $220.0K | $177.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | $100.0K | · | · | · | · | |
| Restructuring | · | · | $200.0K | $500.0K | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $448.0K | · | · | · | $-3M | · | · | · | $-1M | · | · | · | $-6M | · | · | |
| Operating Cash Flow | $2M | $-167.0K | $2M | $-1M | $2M | $-3M | $865.0K | $4M | $1M | $-2M | $-43.0K | $-4M | $-2M | $-4M | $-112.0K | $-1M | |
| CapEx | $617.0K | $425.0K | $86.0K | $229.0K | $164.0K | $63.0K | $395.0K | $191.0K | $286.0K | $139.0K | $43.0K | · | · | · | · | · | |
| Investing Cash Flow | $-487.0K | $-122.0K | $-4M | $-4M | $-103.0K | $-1.0K | $-332.0K | $-6M | $2M | $-139.0K | $2M | $-10M | $-64.0K | $5M | $3M | $-15M | |
| Stock Issued | · | · | $0 | $8M | $0 | $0 | $4M | $4M | $2M | $560.0K | $1M | $14M | $0 | $0 | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $560.0K | · | · | · | · | · | · | |
| Financing Cash Flow | $-683.0K | $-813.0K | $-1M | $7M | $-650.0K | $-783.0K | $3M | $2M | $2M | $178.0K | $-742.0K | $13M | $-130.0K | $-631.0K | $-6M | $-2M | |
| Net Change in Cash | $910.0K | $-1M | $-3M | $1M | $1M | $-4M | $3M | $475.0K | $5M | $-2M | $1M | $-1M | $-2M | $792.0K | $-3M | $-18M | |
| Free Cash Flow | · | $-592.0K | · | · | · | $-4M | · | · | · | · | · | · | · | · | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 18.2% | 16.7% | · | 14.3% | 15.6% | 16.1% | · | 22.0% | 17.6% | 13.5% | · | 9.3% | 5.7% | 13.2% | · | 4.2% | |
| Operating Margin | -6.0% | -8.5% | · | -10.0% | -8.4% | -7.2% | · | 6.8% | 2.0% | -5.8% | · | -7.3% | -16.4% | -7.3% | · | -19.8% | |
| Net Margin | -6.6% | -9.3% | · | -11.0% | -9.3% | -8.0% | · | 5.9% | 1.3% | -7.6% | · | -7.9% | -18.3% | -8.9% | · | -22.4% | |
| EBITDA Margin | -6.0% | -5.6% | · | -10.0% | -8.4% | -4.3% | · | 6.8% | 2.0% | -3.4% | · | -7.3% | -16.4% | -6.4% | · | -19.8% | |
| ROA | -2.1% | -2.9% | · | -3.1% | -2.8% | -2.9% | · | 3.0% | 0.75% | -3.8% | · | -3.5% | -6.8% | -4.5% | · | -7.4% | |
| ROE | -3.6% | -4.8% | · | -5.3% | -5.5% | -5.8% | · | 6.6% | 2.1% | -10.4% | · | -9.9% | -22.3% | -45.2% | · | -30.8% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.7 | · | 3.9 | 2.9 | 2.9 | · | 2.4 | 2.0 | 1.8 | · | 1.3 | 1.6 | 2.0 | · | 2.2 | |
| Quick Ratio | 1.7 | 1.9 | · | 2.3 | 1.9 | 1.9 | · | 1.5 | 1.5 | 1.2 | · | 0.8 | 0.8 | 1.1 | · | 1.1 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.4 | 0.4 | · | 0.4 | 1.0 | 0.7 | · | 0.9 | |
| LT Debt / Equity | 0.2 | 0.2 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.4 | 0.4 | · | 0.2 | 0.5 | 0.5 | · | 0.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -3.1 | · | -4.2 | -7.5 | -3.7 | · | -7.8 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.4 | · | 0.5 | 0.6 | 0.5 | · | 0.4 | 0.4 | 0.5 | · | 0.3 | |
| Inventory Turnover | 4.2 | 3.6 | · | 2.8 | 2.7 | 2.9 | · | 3.9 | 3.6 | 3.4 | · | 4.1 | 3.1 | 3.1 | · | 4.0 | |
| Receivables Turnover | 2.2 | 1.9 | · | 1.9 | 1.7 | 1.8 | · | 3.1 | 3.2 | 2.6 | · | 2.8 | 2.7 | 3.0 | · | 2.8 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $8.83 | $0.91 | · | $0.94 | $0.88 | $0.92 | · | $0.90 | $0.76 | $0.70 | · | $0.76 | $0.57 | $1.00 | · | $1.45 | |
| Revenue / Share | $4.49 | $0.44 | · | $0.44 | $0.47 | $0.55 | · | $0.87 | $0.81 | $0.77 | · | $0.86 | $0.98 | $1.07 | · | $1.78 | |
| Cash Flow / Share | · | $-0.00 | · | · | · | $-0.10 | · | · | · | $-0.08 | · | · | · | $-0.21 | · | · | |
| Cash / Share | $2.65 | $0.24 | · | $0.35 | $0.36 | $0.33 | · | $0.38 | $0.38 | $0.22 | · | $0.27 | $0.53 | $0.87 | · | $1.16 | |
| EPS (TTM) | $-0.80 | $-0.15 | · | $-0.16 | $-0.07 | $-0.01 | · | $-0.03 | $-0.14 | $-0.33 | · | $-0.16 | $-0.32 | $-0.57 | · | $-2.54 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $69M | $68M | · | $76M | $88M | $98M | · | $99M | $94M | $87M | · | $81M | $76M | $76M | · | $69M | |
| Net Income TTM | $-5M | $-5M | · | $-6M | $-2M | $-264.0K | · | $-1M | $-5M | $-8M | · | $-9M | $-12M | $-13M | · | $-25M | |
| Market Cap | $22M | $35M | · | $47M | $29M | $39M | · | $128M | $55M | $49M | · | $59M | $92M | $23M | · | $15M | |
| Enterprise Value | $20M | $34M | · | $42M | $25M | $36M | · | $124M | $51M | $51M | · | $60M | $92M | $21M | · | $16M | |
| P/E | -6.9 | -5.9 | · | -7.5 | -12.1 | -113.0 | · | -132.3 | -12.6 | -5.0 | · | -13.0 | -17.1 | -3.2 | · | -0.5 | |
| P/S | 0.3 | 0.5 | · | 0.6 | 0.3 | 0.4 | · | 1.3 | 0.6 | 0.6 | · | 0.7 | 1.2 | 0.3 | · | 0.2 | |
| P/B | 0.6 | 1.0 | · | 1.3 | 1.0 | 1.2 | · | 4.4 | 2.3 | 2.4 | · | 2.8 | 9.6 | 1.8 | · | 0.9 | |
| P / Tangible Book | 0.9 | 1.4 | · | 1.8 | 1.5 | 1.9 | · | 7.2 | 4.5 | 5.4 | · | 6.1 | 10.7 | 2.0 | · | 1.0 | |
| P / Cash Flow | · | -210.4 | · | · | · | -11.1 | · | · | · | -20.6 | · | · | · | -5.9 | · | · | |
| EV / Revenue | 0.3 | 0.5 | · | 0.6 | 0.3 | 0.4 | · | 1.3 | 0.5 | 0.6 | · | 0.7 | 1.2 | 0.3 | · | 0.2 | |
| Earnings Yield | -14.5% | -16.9% | · | -13.3% | -8.2% | -0.88% | · | -0.76% | -8.0% | -19.9% | · | -7.7% | -5.9% | -31.5% | · | -192.4% |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $69M | $101M | $84M | $73M | $62M |
| Marża Brutto % | 16.9% | 17.2% | 10.4% | 5.6% | -3.9% |
| Marża Operacyjna % | -6.8% | 0.60% | -8.0% | -23.1% | -49.0% |
| Zysk netto | $-5M | $-480.0K | $-8M | $-19M | $-33M |
| Rozwodniony EPS | $-0.15 | $-0.03 | $-0.37 | $-1.31 | $-3.83 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 0.2 | 0.3 | 0.4 | 0.7 | 8.1 |
| Wskaźnik bieżący | 4.0 | 2.6 | 1.7 | 2.0 | 1.7 |
| Wskaźnik Szybkości | 2.0 | 1.7 | 1.2 | 0.9 | 0.9 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $-1M | $3M | · | · | · |
Właściciele instytucjonalni (13F) 36 emitentów · $3.0M łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Posiadacze
36
Wartość posiadanych akcji
$3.0M
Nowe pozycje
6
Zamknięte pozycje
15
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 6 (-8 vs poprzedni kw.) | 15 (+10 vs poprzedni kw.) | 7 (-3 vs poprzedni kw.) | 9 (0 vs poprzedni kw.) | -598K |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1 165 089 | 1 396 990 | 38,59% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $677 668 | 1 229 888 | 22,44% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $213 901 | 364 061 | 7,08% | Akcje |
| RENAISSANCE TECHNOLOGIES LLC | $197 999 | 359 672 | 6,56% | Akcje |
| JANE STREET GROUP, LLC | $134 998 | 245 229 | 4,47% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $128 196 | 232 660 | 4,25% | Akcje |
| Wealthspire Advisors, LLC | $83 587 | 151 838 | 2,77% | Akcje |
| BlackRock, Inc. | $79 688 | 144 756 | 2,64% | Akcje |
| STATE STREET CORP | $55 548 | 100 904 | 1,84% | Akcje |
| NORTHERN TRUST CORP | $50 570 | 91 862 | 1,67% | Akcje |
| UBS Group AG | $38 505 | 70 010 | 1,28% | Akcje |
| PANAGORA ASSET MANAGEMENT INC | $38 179 | 69 353 | 1,26% | Akcje |
| CORSAIR CAPITAL MANAGEMENT, L.P. | $27 525 | 50 000 | 0,91% | Akcje |
| LPL Financial LLC | $22 163 | 40 259 | 0,73% | Akcje |
| WealthTrust Axiom LLC | $18 166 | 33 000 | 0,60% | Akcje |
| Richmond Brothers, Inc. | $16 851 | 30 611 | 0,56% | Akcje |
| Spartan Wealth Advisory Services LLC | $13 768 | 25 010 | 0,46% | Akcje |
| TWO SIGMA SECURITIES, LLC | $13 621 | 24 743 | 0,45% | Akcje |
| Tower Research Capital LLC (TRC) | $7 919 | 14 386 | 0,26% | Akcje |
| Burford Brothers, Inc. | $7 799 | 14 168 | 0,26% | Akcje |
| XTX Topco Ltd | $6 157 | 11 184 | 0,20% | Akcje |
| Vanguard Global Advisers, LLC | $5 825 | 10 571 | 0,19% | Akcje |
| Savvy Advisors, Inc. | $5 505 | 10 000 | 0,18% | Akcje |
| WELLS FARGO & COMPANY/MN | $5 498 | 9 987 | 0,18% | Akcje |
| MORGAN STANLEY | $2 379 | 4 321 | 0,08% | Akcje |
| SHP Wealth Management | $782 | 1 421 | 0,03% | Akcje |
| IFG Advisory, LLC | $369 | 670 | 0,01% | Akcje |
| GROUP ONE TRADING LLC | $255 | 463 | 0,01% | Akcje |
| OSAIC HOLDINGS, INC. | $244 | 445 | 0,01% | Akcje |
| JONES FINANCIAL COMPANIES LLLP | $168 | 258 | 0,01% | Akcje |
| COMERICA BANK | $136 | 163 | 0,00% | Akcje |
| BARCLAYS PLC | $115 | 209 | 0,00% | Akcje |
| FIFTH THIRD BANCORP | $90 | 163 | 0,00% | Akcje |
| GSA CAPITAL PARTNERS LLP | $38 | 69 800 | 0,00% | Akcje |
| Farther Finance Advisors, LLC | $21 | 39 | 0,00% | Akcje |
| FMR LLC | $3 | 6 | 0,00% | Akcje |
Aktywiści i właściciele 5%+ 15 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Richmond Brothers, Inc., RBI Private Investment I, LLC, RBI Private Investment II, LLC, The RBI Opportunities Fund, LLC, The RBI Opportunities Fund II, LLC, RBI PI Manager, LLC, Richmond Brothers 401(k) Profit Sharing Plan, David S. Richmond, Matthew J. Curfman ×18 zgłoszenia | 6 września 2023 | · | Pierwotne zgłoszenie | · | SEC |
| Robert L. Chioini ×10 zgłoszenia | 29 grudnia 2017 | · | Pierwotne zgłoszenie | · | SEC |
| David Hagelstein Charitable Remainder Unitrust dated November 20, 2003, as amended, David A. Hagelstein | 13 sierpnia 2013 | · | Pierwotne zgłoszenie | · | SEC |
| Thomas E. Klema ×3 zgłoszenia | 1 lipca 2013 | · | Pierwotne zgłoszenie | · | SEC |
| Thomas E. Klema (2) | 23 marca 2012 | · | Pierwotne zgłoszenie | · | SEC |
| David Hagelstein Charitable Remainder Unitrust dated November 20, 2003, David A. Hagelstein | 8 grudnia 2011 | · | Pierwotne zgłoszenie | · | SEC |
| David Hagelstein Charitable Remainder Unitrust Agreement, dated November 20, 2003, David A. Hagelstein, individually and the David A. Hagelstein Revocable Living Trust, dated October 27, 1993 ×4 zgłoszenia | 31 marca 2011 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Niezgłoszona osoba raportująca | 13 lutego 2007 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Niezgłoszona osoba raportująca | 13 lutego 2007 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Niezgłoszona osoba raportująca | 6 lutego 2006 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Niezgłoszona osoba raportująca | 27 grudnia 2005 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Niezgłoszona osoba raportująca | 27 grudnia 2005 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Niezgłoszona osoba raportująca | 18 lipca 2005 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Niezgłoszona osoba raportująca | 22 kwietnia 2005 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Niezgłoszona osoba raportująca | 23 stycznia 2004 | · | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 34 insiderów · 18 dyrektorzy generalni · 18 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Mark Strobeck | President and CEO | 1 lipca 2026 A | 62 349 | 0 | 0 | $0 |
| Russell H Ellison | President and Chief Executive Officer | 3 maja 2021 A | 12 050 | 0 | 0 | $0 |
| Stuart M Paul | Chief Executive Officer | 4 września 2019 F | 330 056 | 0 | 0 | $0 |
| CHIOINI ROBERT L | Chairman, President and CEO | 15 grudnia 2017 M | 2 549 907 | 0 | 0 | $0 |
| Jesse Neri | SVP and CFO | 1 lipca 2026 A | 27 239 | 0 | 1 | $-744 |
| Russell Skibsted | EVP, Chief Financial Officer and Chief Business Officer | 9 września 2022 A | · | 0 | 0 | $0 |
| Angus W. Smith | Chief Financial Officer | 28 listopada 2019 F | 168 486 | 0 | 0 | $0 |
| Thomas E Klema | Vice President, CFO | 15 grudnia 2017 M | 671 492 | 0 | 0 | $0 |
| Heather Hunter | Chief Operating Officer | 1 lipca 2026 A | 28 007 | 0 | 2 | $-5 822 |
| Megan C. Timmins | EVP, CLO & Secretary | 1 lipca 2026 A | 31 240 | 0 | 0 | $0 |
| Timothy Chole | SVP, Chief Commercial Officer | 20 maja 2025 A | 122 855 | 0 | 0 | $0 |
| Marc L Hoffman | Chief Medical Officer | 17 marca 2023 A | 25 665 | 0 | 0 | $0 |
| Paul E Mcgarry | SVP, Finance and CAO | 17 marca 2023 A | 28 515 | 0 | 0 | $0 |
| Raymond Dennis Pratt | Chief Development Officer | 3 maja 2021 A | 353 358 | 0 | 0 | $0 |
| Ajay Gupta | Sr. VP & Chief Scientific Off. | 26 kwietnia 2020 F | 574 700 | 0 | 0 | $0 |
| David Kull | Principal Accounting Officer | 25 kwietnia 2019 A | 13 270 | 0 | 0 | $0 |
| Annamaria T Kausz | VP of Drug Development | 23 września 2011 A | · | 0 | 0 | $0 |
| Richard C Yocum | VP - Clin. Dev. & Med. Affairs | 15 stycznia 2010 A | · | 0 | 0 | $0 |
| Joseph H Dawson | Dyrektor | 1 lipca 2026 A | 12 133 | 0 | 0 | $0 |
| Joan Lau | Dyrektor | 1 lipca 2026 A | 20 944 | 0 | 0 | $0 |
| Robert S Radie | Dyrektor | 1 lipca 2026 A | 23 985 | 0 | 0 | $0 |
| Allen Nissenson | Dyrektor | 1 lipca 2026 A | 23 892 | 0 | 0 | $0 |
| John G Cooper | Dyrektor | 1 lipca 2026 A | 23 670 | 0 | 1 | $-4 419 |
| Andrea Heslin Smiley | Dyrektor | 20 maja 2025 A | 142 062 | 0 | 0 | $0 |
| Mark H Ravich | Dyrektor | 20 maja 2025 A | 148 831 | 0 | 0 | $0 |
| John Peter Mclaughlin | Dyrektor | 17 czerwca 2021 A | 136 974 | 0 | 0 | $0 |
| Benjamin Wolin | Dyrektor | 6 czerwca 2019 A | 27 710 | 0 | 0 | $0 |
| Robin L Smith | Dyrektor | 6 czerwca 2019 A | 31 366 | 0 | 0 | $0 |
| Lisa N Colleran | Dyrektor | 6 czerwca 2019 A | 18 674 | 0 | 0 | $0 |
| Patrick J Bagley | Dyrektor | 19 marca 2018 A | 116 307 | 0 | 0 | $0 |
| Ronald D Boyd | Dyrektor | 19 marca 2018 A | 42 678 | 0 | 0 | $0 |
| Kenneth L Holt | Dyrektor | 16 marca 2017 S | 12 630 | 0 | 0 | $0 |
| Irrevocable Larson Family Investment Trust | Posiadacz 10% | 11 kwietnia 2025 P | 3 557 500 | 0 | 0 | $0 |
| HAGELSTEIN DAVID A | Posiadacz 10% | 28 stycznia 2013 J | 1 360 700 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 2 fundusze ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
RMTI Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
ocena · 8 analityków
KUP
Średni cel
$20.00
+131,2%
2 25,0%
Mocne kupno
5 62,5%
Kup
1 12,5%
Trzymaj
0 0,0%
Sprzedaj
0 0,0%
Mocna sprzedaż
12-miesięczny cel cenowy
2 analityków · 2026-10-03Średnia cel $20.00 +131,2%
Niski$20.00
Średnia$20.00
Wysoki$20.00
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| RMTI | $33M | -5.5 | -31.8% | -7.7% | -15.8% | 16.9% |
| UTMD | $178M | 16.1 | -5.8% | 29.3% | 9.5% | 57.1% |
| RXST | $430M | -11.0 | -3.9% | -29.0% | -14.0% | 76.6% |
| SKYA | · | · | · | · | · | · |
| TELA | $53M | -1.4 | 15.8% | -48.4% | -501.1% | 67.7% |
| NSPR | $77M | -2.3 | 28.1% | -543.3% | -129.3% | 29.5% |
| ADVB | $15M | -4.4 | · | · | -159.1% | · |
| LUCY | · | · | · | · | · | · |
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Źródło: SEC 10-Q złożone Sie 13, 2026